7 min listen
Tom Gadek Part 2: Discovery and development of Lifitegrast to treat dry eye syndrome: Pharmacology
FromiBiology Videos
Tom Gadek Part 2: Discovery and development of Lifitegrast to treat dry eye syndrome: Pharmacology
FromiBiology Videos
ratings:
Length:
33 minutes
Released:
Dec 22, 2020
Format:
Podcast episode
Description
In his second lecture, Gadek reviews the molecular mechanism of dry eye syndrome, focusing on the role of inflammation and T-cells in this disorder. By analyzing clinical trial data from other drugs developed to treat dry eye, Gadek and colleagues confirmed the importance of LFA-1 as a possible target. LFA-1 is a surface protein on T-cells that binds to ICAM-1 on antigen presenting cells, T-cells, and epithelial cells and causes inflammation. Gadek and his colleagues developed Lifitegrast, a small molecule that serves as an ICAM-1 mimetic. By binding to LFA-1 on T-cells, Lifitegrast inhibits the binding of ICAM-1 and therefore inhibits the inflammation associated with dry eye syndrome.
Released:
Dec 22, 2020
Format:
Podcast episode
Titles in the series (92)
Esteban Burchard Part 3: Inclusion of Minorities in Science and Medicine: An Inclusive Future: There is ample evidence that race can be a major factor in health outcomes. But racial and ethnic minorities are underrepresented in clinical and biomedical research. In this series, Dr. Esteban Burchard talks about the consequences of this underrepres... by iBiology Videos